NASC
Can B Corp
$0.01
+0.00 (+0.00%)
At close · Jul 16
Market Cap
$985,945
Shares
75,841,988
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.01
Open$0.01
Day$0.01–0.01
52W$0.01–0.04
Avg vol 30d28K
Short int2K · 0.0% float · 1.0d
Short vol67%
DataJan 2020–Jul 2026
Filing10-Q · Nov 19
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Nov 19, 2024
Equibles Rating
blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 16.7 · calm
Equity put/call 0.67
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−29%
below
Price vs 50-day avg
−14%
below
RSI (14)
42
neutral
MACD trend
Negative
52-week position
8%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−14%
trailing
6-month return
−59%
trailing
YTD return
−25%
this year
Relative strength
−69%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Flat
No 13F holder data
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.00% of float · ▲ +4600.0% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
No 13F holder history
Squeeze score
33
low risk · 0–100
Fundamentals
Revenue growth
+29%
Y/Y
Gross margin
292%
contracting
EPS growth
+82%
Y/Y
Free cash flow
$-1.3M
Balance sheet
$34.0K
net cash
Quant / Vol
risk profile
Volatility
202%
annualized · 1-yr
Max drawdown
−71%
past year
ATR
10.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−29%
Bearish
Price vs 50-day avg
−14%
Bearish
RSI (14)
42
Neutral
MACD trend
Negative
Bearish
52-week position
8%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 1 of 6
Trend (MA cross)
No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Flat
No 13F holder data
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.00% of float · ▲ +4600.0% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
No 13F holder history
Price context
position in its 52-week range
52-wk low $0
Now $0 · 8%
52-wk high $0
vs 200-day avg -29%
vs 50-day avg -14%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NASC
this stock
Can B Corp
|
$985,945 | -25.0% | +29.0% | — | 0.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$53.43B | +7.3% | — | — | 0.2% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$51.90B | — | — | — | 0.0% |
|
GALDY
Galderma Group AG/ADR
|
$49.13B | -0.2% | — | — | 0.0% |
|
HLN
Haleon plc
|
$44.52B | +0.0% | — | — | 0.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionShort & Settlement
Financials
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NASC | +0.0% | -14.3% | -58.6% | -25.0% | -25.0% |
| SPY | +1.3% | -0.2% | +10.1% | +1.1% | +10.7% |
| vs SPY | -1.3% | -14.1% | -68.8% | -26.1% | -35.7% |